Trial reportAlzheimer's research & therapy2022
Evaluation of tau deposition using
Trial report in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Associations of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Test-retest reliability of FreeSurfer measures of neurodegeneration.NeuroImage · 2026Article
- Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.Ochsner journal · 2026Article
- DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent pathways: multimodal PET/MRI study.European journal of nuclear medicine and molecular imaging · 2025Article
- Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Investigating the Correlation Between Gray Matter Volume Changes and Cognitive Function Among Alzheimer's Disease Patients: An MRI-Based Analysis.Actas espanolas de psiquiatria · 2025Article
- Kinetic modeling ofEJNMMI research · 2025Article
- Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Advances in the use of structural and diffusion magnetic resonance imaging for characterizing SCD and MCI due to Alzheimer's disease.Frontiers in neuroscience · 2025Review
- Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025Article
- Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- One-Year Longitudinal Changes in Tau Accumulation on [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging.Brain communications · 2024Article
- [18F]PI-2620 Tau PET signal across the aging and Alzheimer's disease clinical spectrum.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- [Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ability of
methodsSubjects with a diagnosis of MCI due to AD or mild AD dementia and a visually amyloid-positive
resultsPercentage of visually tau-positive scans increased with amyloid-beta deposition measured in
conclusionsThe findings support the hypothesis that
trial registrationData used in this manuscript belong to a tau PET imaging sub-study of the elenbecestat MissionAD Phase 3 program registered in ClinicalTrials.gov ( NCT02956486 ; NCT03036280 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.